
Presenter(s): Arthur Robin Williams, MD, MBE and Peter Treitler, PhD
Target Audience: This activity is designed for physicians, nurses, psychologists, social workers, physician assistants, pharmacists, interprofessional team, residents/fellows, medical students, other mental health clinicians. This activity is accredited for physicians, nurses, social workers, physician assistants, pharmacists, interprofessional team, and other health professionals.
Credit Designations Available: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Social Work CE Credit, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Webinar Description: This session explores the clinical and policy landscape of providing medications for opioid use disorder (MOUD) in jails, prisons, and reentry settings. Dr. Arthur Robin Williams and Dr. Peter Treitler review recent research on the effectiveness of MOUD in reducing overdose and improving post-release treatment engagement. The session highlights key differences among methadone, buprenorphine, and extended-release naltrexone, including regulatory and logistical considerations unique to correctional environments. Learners will examine policy updates, case-based examples, and implementation strategies that support evidence-based treatment access. The session also addresses interdisciplinary collaboration, diversion concerns, and continuity of care across incarceration and reentry.
Educational Objectives:
-
- Describe prevalence of opioid use disorder and overdose risk in justice-involved populations;
- Summarize evidence on outcomes of MOUD provided in jails and prisons;
- Compare and contrast methadone, buprenorphine, and extended-release naltrexone in correctional settings;
- Outline key legal and policy frameworks that impact MOUD access and implementation;
- Identify implementation strategies for providing MOUD in correctional settings and linking patients to treatment post-release.